To hear about similar clinical trials, please enter your email below
Trial Title:
Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer
NCT ID:
NCT06148298
Condition:
Cancer of Pancreas
Conditions: Official terms:
Pancreatic Neoplasms
Conditions: Keywords:
cancer
pancreas
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Other
Intervention:
Intervention type:
Other
Intervention name:
Non-Human Subject Research study.
Description:
This is a Non-Human Subject Research study. There is no intervention. All participants
are de-identified.
Arm group label:
Pancreatic Ductal Adenocarcinoma
Summary:
The goal of this research is to use chromatin immunoprecipitation, a method used to study
protein-DNA interaction, as a tool to diagnose and prognose pancreatic ductal
adenocarcinoma in human samples.
This is a Non-Human Subject Research study. All participants are de-identified.
Detailed description:
Pancreatic ductal adenocarcinoma (PDAC) is a neoplastic disease which accounts for "90%
of pancreatic malignancies," and has a 5-year survival rate of only 9%. The dismal nature
of the PDAC diagnosis, which has a median survival time of about one year, can be
attributed in part to late detection. In fact, the Cancer of Pancreas Screening-5 study
demonstrated a 73.3% survival rate in participants whose PDAC was found early through
surveillance via MRI and endoscopic ultrasound. This eightfold increase in survival rate
suggests the inherent efficacy of PDAC screening, however, with the median cost of a full
MRI being about $2,000, there is a significant barrier to entry for PDAC screening. As a
result, finding a cost-effective alternative to PDAC screening could improve survival
rates and lower costs, both directly and indirectly. Liquid biopsy could prove to be a
valuable tool in the early diagnosis of PDAC, as it provides a non-invasive way to detect
the presence of a disease state such as PDAC. Chromatin immunoprecipitation (ChIP), a
type of liquid biopsy used to study protein-DNA interaction, is a promising method at the
forefront of cancer research, and has been proven to be capable of detecting
tumor-specific transcriptional activity. Additionally, the assay has shown promise in
diagnosis and prognosis of disease state. Currently, few (if any) modalities of liquid
biopsy in pancreatic cancer use ChIP, and other forms of liquid biopsy have proven to
lack sensitivity and specificity. Thus, the aim of this research is to utilize the ChIP
assay as a diagnostic and prognostic tool in PDAC by detecting and quantifying tumoral
gene expression.
Criteria for eligibility:
Study pop:
The investigators want to control for approximate age and have two participants of each
gender, and are looking to get 4 without Pancreatic Ductal Adenocarcinoma (PDAC), and 4
of each stage of PDAC (1 through 4).
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- 18 years old or older
- Pancreatic cancer patients
Exclusion Criteria:
- Children may not register
- Persons who are unable to consent may not register
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
University of Central Florida
Address:
City:
Orlando
Zip:
32816
Country:
United States
Status:
Recruiting
Start date:
May 24, 2023
Completion date:
May 2024
Lead sponsor:
Agency:
University of Central Florida
Agency class:
Other
Source:
University of Central Florida
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06148298
